Global Turner Syndrome Market - 2024-2031

Global Turner Syndrome Market - 2024-2031

The global Turner syndrome market reached US$ 4,126.40 million in 2023 and is expected to reach US$ 6,651.68 million by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

Turner syndrome is a condition in which one X chromosome is missing, which results in several developmental problems. This condition is only seen in females and the reason is unknown and is believed to result from a random event. The most common symptoms seen in a Turner syndrome patient are short stature, under-developed ovaries, and learning disabilities in some patients. The risk of congenital heart defects, kidney abnormalities, and hypothyroidism is higher in Turner syndrome patients.

The treatment of Turner syndrome majorly focuses on symptomatic relief. The most common treatments are growth hormone therapy, and sex hormone replacement therapy along with constant health checkups and psychological therapy. Majority of women with Turner syndrome may not conceive, hence fertility treatment is one of the therapeutic options, but it is also associated with risks.

Market Dynamics: Drivers

Rising research and development activities

The major symptoms of Turner syndrome are short stature and underdevelopment of ovaries. To treat these symptoms, the major therapeutic options are growth hormone supplementation, and sex hormone replacement therapy. The growth hormones and sex hormone replacement therapy have long been approved by regulatory bodies for many conditions. Several companies have been investing to bring better products into the market. These products are also aimed to treat symptoms of Turner syndrome.

For instance, in June 2023, the U.S. FDA approved Pfizer’s NGENLA (somatrogon), a once-weekly human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. This hormone can be used in the treatment of Turner syndrome and growth hormone deficiency disease (GHD).

In May 2023, Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion by recommending once-weekly Sogroya (somapacitan) for the replacement of endogenous growth hormone in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency and Turner syndrome.

Moreover, a phase 2 clinical trial was initiated in February 2023, for a biologic drug Lonapegsomatropin, a long-acting growth hormone product in prepubertal individuals with Turner syndrome. The trial is sponsored by Ascendis Pharma A/S and aims to finish by June 2026.

In March 2024, a phase 2 trial was initiated for the drug Vosoritide for Turner syndrome patients. Vosoritide is a C-type natriuretic peptide (CNP) analog, that targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. It is hypothesized that patients with Turner syndrome and short stature will respond to vosoritide treatment leading to increased growth velocity.

Moreover, the rising awareness and increasing diagnosis rate, growing prevalence are the major factors that are expected to further boost the market growth.

Restraints

The high cost of treatment can be a restraining factor for the market growth in the forecast period. The patient with Turner syndrome must take long-term treatment, the growth hormones and the estrogens which are mainstay options, can be expensive for some patient populations.

For more details on this report - Request for Sample

Segment Analysis

The global Turner Syndrome market is segmented based on disorder type, treatment type, end-users, and region.

The hormone replacement therapy in the treatment type segment accounted for major share for the global Turner syndrome market

The administration of ERT and GH is the main treatment for Turner syndrome. Despite being distinct therapeutic approaches, GHT and ERT frequently complement one another to maximize the development potential and general health of people with Turner syndrome. The first goal of GHT is for girls to reach a height that will not place physical limits on them and to begin sexual maturation at a similar age to their peers. When a person reaches adolescence and growth hormone therapy has produced adequate linear development, estrogen therapy is typically started. At this point, the administration of estrogen aids in the development of secondary sexual traits and the accomplishment of typical pubertal developmental milestones.

According to the National Health Service (NHS), growth hormone therapy is a daily injection, starting at around 5 or 6 years of age or later. It's usually continued until 15 or 16, helping the girl gain on average around 5cm (about 2in) in height. The treatment span would be close to 10 years. Whereas hormone replacement therapy is given to Turner syndrome patients until they attain menopause. Oestrogen replacement therapy is usually started around the time of normal puberty which is around 11 years of age. This is usually continued till they attain 50 years of age.

Hence, hormone therapy plays a crucial role in patients with Turner syndrome and is expected to have the highest market share in the treatment type segment.

Geographical Analysis

North America is expected to dominate the market with a 47.6% share in the global Turner syndrome market.

North America is well known for its advancements in the healthcare industry. The major countries in the region such as the U.S. and Canada are well known for their investments in healthcare. The favorable yet stringent regulatory policies, favorable environment for research and development activities, higher demand for advanced therapeutics, and high investments in the industry are the factors that are contributing to the region’s dominance.

Moreover, the region has the highest prevalence of Turner syndrome. For instance, according to the National Organization for Rare Disorders, Turner syndrome affects approximately 1 in 2,000-2,500 live female births, and nearly 70,000 females in the United States have Turner syndrome. Due to the availability of advanced healthcare systems, well well-trained physicians, the diagnosis rate is this condition is high, and patients in the region get timely diagnosis and treatment with advanced therapeutical modalities.

Market Segmentation

By Disorder Type
• Monosomy Turner Syndrome
• Mosaic Turner Syndrome

By Treatment Type
• Hormone Replacement Therapy
Growth Hormone Therapy
Estrogen Replacement Therapy (ERT)
Thyroid Replacement Therapy
• Supplemental Therapy

By End-Users
• Hospitals
• Specialty Clinics
• Homecare
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the Turner Syndrome market include Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Merck KGaA, Ferring B.V., F. Hoffmann-La Roche Ltd, Sandoz Inc., Ascendis Pharma, AnkeBio Co., Ltd, and Changchun GeneScience Pharmaceutical Co., Ltd. among others.

Why Purchase the Report??
• To visualize the global TTurner Syndrome market segmentation based on disorder type, treatment type, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Turner Syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Turner Syndrome market report would provide approximately 62 tables, 51 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies